Abstracts

OVERT GUT IL-32 ISOFORM EXPRESSION DURING TREATED HIV INFECTION: REGULATION BY IL-17A

The interplay between intestinal epithelial cells (IEC) and Th17 cells is key for mucosal immunity homeostasis. HIV infection provokes intestinal barrier function impairment and chronic immune activation, which are not normalized by antiretroviral therapy (ART). Such alterations coincide with the overexpression of IL-32, a newly described cytokine, with multiple isoforms. IL-32 overexpression was predictive of…

SYSTEMIC AND VASCULAR INFLAMMATION PREDICT COMORBIDITIES IN TREATED HIV INFECTION

Although inflammation and immune dysfunction are implicated in pathogenesis of comorbidities in treated people with HIV (PWH), whether an immune risk profile can predict PWH at higher risk of comorbidities is unclear. In the UCD Infectious Diseases cohort study of PWH on anti-retroviral therapy, we measured 24 biomarkers using bead based quantitative ELISA, covering pathways of systemic inflammation…

FECAL CALPROTECTIN IS ELEVATED IN HIV AND RELATED TO SYSTEMIC INFLAMMATION

Fecal calprotectin (FCP), a biomarker of gastrointestinal inflammation, is used in the diagnosis and management of inflammatory bowel disease. HIV infection severely damages gut-associated lymphoid and epithelial tissues leading to gut inflammation, microbial translocation and systemic inflammation/immune activation. We sought to investigate FCP in people with HIV (PWH) for the first time and determine its relationship to HIV-specific…

NON-AIDS—DEFINING EVENTS IN HIV CONTROLLERS VS ART-CONTROLLED PATIENTS

HIV controllers (HICs) are rare persons living with HIV who spontaneously maintain low or undetectable viremia. Low-grade chronic inflammation persisting in this population could lead to higher rates of non-AIDS defining events (nADEs) than in patients who achieve low or undetectable viremia on antiretroviral therapy (ART). From the ongoing multicenter ANRS CODEX cohort, we enrolled…

LONG-TERM ELEVATED IL-6 AND D-DIMER AFTER DELAYED ART INITIATION IN THE START TRIAL

Inflammation and coagulation are associated with disease risk among persons with HIV. ART reduces inflammation, but whether time of initiation during infection affects this reduction has not been studied experimentally. We report on the interleukin-6 (IL-6) and D-dimer trajectories in the immediate versus deferred arms of the START trial In participants randomized to immediate (CD4>500…

TOTAL HIV DNA LEVELS DO NOT PREDICT NON-AIDS-DEFINING EVENTS

Despite antiretroviral therapy (ART), individuals with HIV maintain an HIV reservoir with high levels of systemic inflammation and are more likely to have non-AIDs-defining events compared to those without HIV. We performed a case-control study of AIDS Clinical Trials Group (ACTG) participants to assess the relationship of HIV reservoir size with levels of systemic inflammation,…

PRINCIPAL COMPONENTS ANALYSIS TO IDENTIFY BIOMARKERS PREDICTIVE OF NON-AIDS EVENTS

Improvements in technology (new assays, multiplex panels) and large repositories of clinical samples accelerate investigations of numerous individual biomarkers with potential for increased risk of type 1 error. Approaches to combine biomarkers can gain biological understanding and improve statistical efficiency to assess risk of clinical events; however, the best high-dimensional analytic methods are not clear.…